european journal
of gynaecological oncology
an International Journal
Founding Editor
| A. Onnis |
| Montréal (Canada) |
| Editors-in-Chief |
M. Marchetti
Montréal (Canada) |
P. Bösze
Budapest (Hungary) |
Associate Editor
T. Maggino
Padua (Italy)
Assistant Editor
J. Wilson
San Diego - CA (USA)
| Editorial Board |
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA) |
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel) |
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan) |
Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal,
Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com
- www.irog.net
Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 -
Fax (39) 049 8752018
|
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN
0392-2936) publishes original peer reviewed works in the fields of female
genital cancers and related subjects and also proceedings of gynecologic
oncology society meetings all over the world. The Journal is covered by
CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/
Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
European Journal of Gynaecological
Oncology
www.irog.net
General Information
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936)
publishes original peer reviewed work, preferably brief reports, in the
fields of female genital cancers and related subjects – prevention,
early detection, epidemiology, pathology, diagnosis, management –
and also proceedings of Gynaecologic Oncology Society meetings all over
the world.
The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT,
INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing
editorial articles in the “Distin-guished Expert Series” and
original research papers, case reports, letters to the Editor, book reviews
and newsletters.
The Journal was founded in 1980 – the second gynaecologic oncology
hyperspecialization journal in the world. Its aim is the dif-fusion of
scientific, clinical and practical progress and knowledge in female neoplastic
diseases in an interdisciplinary approach among gynaecologists, oncologists,
radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists
and so on.
ANNOUNCEMENTS regarding meetings, postgraduate courses
and symposia will be accepted 6 months before publication and will be
published free of charge.
BOOK SAMPLES for review should be sent to the Editorial
offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright
Clearance Center, Inc. Reproductions are not allowed without the written
consent of the Publisher. All photocopy fees should be paid to the Copyright
Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating
the ISSN number, the volume and the first and last page numbers of each
article copied.
ADVERTISING INFORMATION: advertising orders and inquiries
may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc,
Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640
- Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the
editorial staff and the printer to eliminate misleading or inaccurate
infor-mation, the publisher accepts no responsibility for the consequences
of faultful or incorrect information. The authors recognize that the editor
and publisher have no responsibility and are indemnified against any liability
or claim that may result from the publication of misleading or incorrect
data.
SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September
and November); one volume per year. Subscriptions start from January and
are automatically renewed if not cancelled by the end of September.
Subscriptions include six issues per year plus supplements, monographs
and all official communications of Meetings, Courses, Symposia and all
scientific activities of Gynaecologic Oncology Societies all over the
world.
Subscriptions are entered with prepayment only. The annual
subscription is $390 US for Institutions, $200 US for Individuals. For
airmail add $30, for receipt add $10 US. Single copy prepaid cost $95
US.
Send subscription requests with cheque or credit card payment (Amex -
Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte
St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only
US Funds are accepted. No bank transfers.
Claims for missing issues can be honoured up to six months.
Changes of address: allow six weeks for all changes to
become effec-tive. All communications should include both old and new
addresses (with postal codes) – better if accompanied by a mailing
label from a recent issue – and should be sent to the printer: La
Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580.
Claims should be made within six months of publication date.
Duplicate copies will not be sent to replace those undelivered through
failure to notify of change of address.
Single copies and back issue and volume information is available from
the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580.
Certain back issues may only be available as photocopies of the originals.
All other business correspondence including orders for offprints and advertising
space and any communication and requests should be addressed to I.R.O.G.
CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC
H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.
IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT
European Journal of Gynaecological
Oncology
www.irog.net
Instructions to Authors
SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN
JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212
MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513,
or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.
Editorial articles for publication in the “Distinguished Expert
Series” should be submitted to P. Bösze, Editor-in-Chief of
this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest,
Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu
When a manuscript is submitted, an acknowledgement card is sent to the
corresponding author within two or three weeks.
Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees.
Authors may be required to modify the manuscript according to the reviewers’
suggestions.
Manuscripts accepted for publication will be copyedited by the editorial
staff for typographical and grammatical mistakes and to guarantee clarity
and conciseness.
Publication time will be the shortest possible based
on scientific and publishing needs. Manuscripts submitted for
publi-cation cannot be returned.
Published papers will become property of the Journal and copyrighted under
I.R.O.G. CANADA Inc.
After six months no grievances will be accepted regarding published articles.
All statements are the responsibility of the authors. Product dosages,
indications and methods referred to in the papers reflect the author’s
experience. No responsibility is assumed by the Editor-in-Chief or the
Publisher for any damage from use of any products, operation methods or
instructions contained in the published materials.
Trade names, trademarks, etc. are protected by the law and regulations.
The Editor-in-Chief and the Publisher cannot accept any legal responsibility
for any errors or omissions that may be made in press, particularly for
information about drug dosage and appli-cation thereof contained in the
Journal. Consult the prescribing information before administering any
drug.
MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted
to biomedical journals” published in the New England Journal of
Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.
Three manuscripts, typed and double spaced should be
submitted with an electronic disk, formatted in Word for Macintosh
or Windows, version 6.0. Manuscripts without an electronic disk
will not be accepted. A cover letter signed by all authors must
state that all authors who have participated in the work take responsibility
for the manuscript which has never been pub lished or submitted for publication
elsewhere. Without a cover letter the publication will not be
possible. Name, address and phone/fax numbers of the Corresponding Author,
responsible for revision and approval of the proofs, should be indicated.
Full-length articles should not exceed 8 printed pages including tables
and references.
After the title page (full title and names of authors,
institutions, eventual acknowledgement for financial support, running
title of no more than 60 characters or spaces), original works should
be arranged in the conventional order: Summary (purpose of investiga-tion,
methods, results, conclusion - about 150 words), Key words, Content
(a 20-word summary), Introduction, Materials and Methods, Results,
Discussion, Conclusion, Acknowledgement (if any), References, Tables,
Legends.
Authors should supply a complete address for reprint requests.
In the text only standard abbreviations can be used and must be avoided
in the title. The full term for which an abbreviation stands should precede
its first use in the summary and text unless it is a standard unit of
measurement.
Authors must give their complete professional identifications
and affiliations, including all academic titles and positions.
Letters to the editor should be brief (500 words or less)
and offer objective, constructive and educational criticism of published
material. The editor reserves the right to publish.
Figures: Two original copies (not negatives) of each
figure are requested. Each figure should have a label on the back indicating
its number, author’s name and top of the figure. Do not write on
the back of the figures and do not mount them on cardboard. If
sending colour pictures advise if they must be printed in colour or black
and white (colour costs ten times more).
Legends should be typed on a separate page with Arabic
numerals corresponding to the illustrations.
Tables should be titled, typed in double space on separate
pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood
abbreviations should be used.
References should be numbered consecutively in the order in which
they are first mentioned in the text. Identify references in
the text, tables, and legends by Arabic numerals in parentheses.
Use the style of the examples below, which are based with slight modifications
on the format used by the U.S. National Library of Medicine in Index Medicus.
The titles of journals should be abbreviated according to the style used
in Index Medicus.
References must be verified by the Author(s) against the original documents.
Examples of correct forms of references are given below:
Articles in Journals: Authors’ surname and initials
(if more than six names, give six followed by “et al.”), Title,
Abbreviated Journal Title, Year of Publication, Volume, Issue and first
page.
Books: Authors’ surname and initials, title of
the book and title of chapter, in: Title, Editor(s), Place, Publisher,
Year, Page.
Acknowledgments will be limited to appropriate professionals
who were contributors to the paper.
PROOFS revised by the editorial staff will
be sent to the corresponding author and should be checked and returned
within ten days. The corresponding author is responsible for detecting
typesetting errors. After this deadline the proofs will be considered
approved. Only essential corrections should be made; extensive changes
will be charged to the authors.
BUSINESS MATTERS
The Journal has no commercial advertisements.
Authors will be expected to contribute to the printing expenses,
tables, figures and postage. For every published article a copy
of the Journal will be provided free of charge. Only payments
in US dollars will be accepted. No bank transfers.
Reprints should be requested with the form enclosed
with the acceptance letter. No free reprints will be supplied.
© By I.R.O.G. CANADA INC. - Publisher - Editorial office
4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3
(Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy
by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy)
- Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s
Court n. 633 - 28-6-1979 |
| |
|
 European Journal of Gynaecological Oncology - Vol. XXX, n. 1, 2009 |
|
| |
|
| CONTENTS |
|
| DISTINGUISHED EXPERT SERIES |
|
| Chemotherapy and the future: microdialysis as a local administration technique |
5 |
F.C. Martins, C.F. de Oliveira - Coimbra, PORTUGAL
Applications and limitations of the microdialysis technique for local-regional chemotherapy are evaluated. |
|
 |
|
| REVIEW ARTICLE |
|
| Bilateral breast metastasis of ovarian carcinoma |
9 |
P. Dursun, F.B. Yanik, E. Kuscu, M. Gultekin, A. Ayhan - Ankara, TURKEY
The clinicopathological features of patients with bilateral breast metastasis originating from ovarian carcinoma are summarized. |
|
| Ovarian transposition for the preservation of ovarian function in young patients with cervical carcinoma |
13 |
P. Dursun, A. Ayhan, F.B. Yanik, E. Kus¸çu - Ankara, TURKEY
Radiotherapy and/or surgery irreversibly destroy the reproductive capacity of young women with cervical carcinoma, however
ovarian transposition (OT) may protect ovarian functions in these patients. Indications, techniques and functional outcomes of
OT are reviewed. |
|
 |
|
| ORIGINAL ARTICLES |
|
| Fractional allelic loss as a potential biomarker of risk prediction in early-stage mucinous ovarian
tumors of low malignant potential |
16 |
K. Nakayama, N. Nakayama, M. Ishibashi, S. Yeasmin, M. Fukumoto, K. Miyazaki - Senday, JAPAN
Non-random chromosome gains and losses with cisplatin-resistant epithelial ovarian cancer was documented. Genes on these
regions were related to drug-resistant phenotypes. |
|
| Radiation therapy in cervical carcinoma: fifteen years experience in a Norwegian health region |
20 |
E. Lorenz, T. Strickert, B. Hagen - Trondheim, NORWAY
A retrospective study on primary radiotherapy for cervical carcinoma is presented together with long-term results on survival
and late tissue reactions. |
|
| The influence of intraoperative tumor rupture on recurrence risk in Stage Ic epithelial ovarian cancer |
25 |
C.S. Goudge, Z. Li, L.S. Downs Jr. - Minneapolis, MN (USA)
In early ovarian cancer, intraoperative tumor rupture carries a negative prognostic significance. The outcomes of patients
assigned to Stage Ic were evaluated for this reason. |
|
| The up-regulation of KCC1 gene expression in cervical cancer cells by IGF-II through the ERK1/2-
MAPK and PI3K/AKT pathways and its significance |
29 |
S. Zhang, X. Wu, T. Jiang,Y. Lu, L. Ma, M. Liang, X. Sun - Shenyang, CHINA
IGF-II can enhance KCC1 gene expression in cervical cancer cells through the ERK1/2MAPK and PI3K/AKT signal transduction
pathways. |
|
| Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case? |
35 |
S. Attard Montalto, A. Hakmi, K.S. Raju, M. Coutts, A.J. Papadopoulos, O. Devaja - Maidstone Kent, UK
A study investigating what proportion of cases showing a well differentiated endometrioid endometrial adenocarcinoma in the
hysterectomy specimen had adverse pathological features or advanced stage disease at the time of presentation. |
|
| Chemotherapy (CT) with radiotherapy versus CT alone for FIGO Stage IIIc endometrial cancer |
40 |
M. Matsuura, T. Suzuki, M. Morishita, R. Tanaka, E. Ito, T. Saito - Sapporo, JAPAN
The outcome of patients affected by FIGO Stage III C endometrial cancer was compared in relation to therapy: CT plus RT
versus CT alone. |
|
| Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that
can affect virgins and young adolescents |
45 |
C. Liebrich, O. Brummer, R. Von Wasielewski, G. Wegener, C. Meijer - T. Iftner, K.U. Petry - Tübingen,
GERMANY
Rare types of adenocarcinoma of the uterine cervix may be unrelated to HPV and differ from common HPV-induced tumours
in the epidemiology and natural course. |
|
| A retrospective analysis of twenty-eight borderline ovarian tumours in adolescent girls |
49 |
P. Tsikouras, V. Liberis, G. Galazios, C. Panagiotidou, S. Bouchlariotou, A.T. Teichmann, G. Maroulis -
Thrace, GREECE
Evaluation of conservative surgical treatment of borderline ovarian tumours in teenagers. |
|
| Inhibitory effects of c-erbB-2 antisense oligonucleotide transfection on uterine endometrial cancer
Ishikawa cell lines |
54 |
F.J. Zhao, S.L. Zhang, L. Ma, H. Gao. Z.H. Zong - Shen Yang, P.R. CHINA
Transfecting c-erbB-2 ASODN can obviously suppress its mRNA and protein expression in ISHIKAWA cells causing cellular
apoptosis and inhibiting cell growth, and may have an important role in the gene therapy of endometrial cancer. |
|
| Effects of quercetin on proliferation, apoptosis, adhesion and migration, and invasion of HeLa cells |
60 |
W. Zhang, F. Zhang - Hubei, CHINA
It was determined that quercetin has the function of inhibiting breeding of HeLa cells inducing apoptosis of the cells that
inhibit adhesion, migration and invasion of HeLa cells. |
|
| Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with
human papillomavirus detected in paraffin-sectioned samples |
65 |
A. Kwa´sniewska, E. Korobowicz, M. Zdunek, M. Skoczv´nski, W. Kwa´sniewski, J. Danilos, A. Go´zdzicka-
Józefiak - Lublin, POLAND
The frequency of occurrence of HPV and co-infection with chlamydia trachomatis and HSV-2 in cervical cancer is reported. |
|
| Clinicopathologic analysis: relationship between endometrial carcinoma and uninvolved endometrium |
71 |
C. Dane, Z. Tatar, B. Dane, A. Cetin - Istanbul, TURKEY
The clinicopathologic features of endometrial carcinoma originating from a hyperplastic base, and histopathologic and clinical
features of endometrial carcinoma originating from an atrophic base were not very different. |
|
| Results of conservative surgery for recurrent borderline ovarian tumors |
75 |
B. Cheng, X. Wan, X. Qian,W. Lv, X. Xie - Hangzhou, CHINA
A second conservative surgery for patients with recurrent borderline ovarian tumors should still be considered for women who
are young and desire preservation of fertility. |
|
| Radical hysterectomy for invasive cervical cancer during pregnancy: A retrospective analysis of a single
institution experience |
79 |
Y. Watanabe, M. Tsuritani, T. Kataoka, K. Kanemura, M. Shiina, H. Ueda, H. Hoshiai - Osaka, JAPAN
Radical hysterectomy in pregnant women can be safely performed on either the fetus in situ or following cesarean section. |
|
| Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists |
82 |
D. Vavilis, M. Zafrakas, D.G. Goulis, K. Pantazis, T. Agorastos, J.N. Bontis - Thessaloniki GREECE
A survey among obstetricians-gynaecologists practising in Greece showed that most physicians would not prescribe hormone
therapy to postmenopausal breast cancer survivors. |
|
| Intraoperative estimation of sentinel lymph nodes in breast cancer by imprint cytology |
85 |
V. Limberis, C. Romanidis, G. Galazios, G. Koutsougeras, N. Papadopoulos, M. Lambropoulou, C.
Simopoulos - Thrace, GREECE
Touch imprint cytology is an alternative solution for intraoperative evaluation of sentinel lymph nodes in breast cancer. |
|
 |
|
| CASE REPORTS |
|
| Primary malignant melanoma arising in an ovarian cystic teratoma |
88 |
T. O’Gorman, A. Olaitan - London, UK
Description of a rare case of primary ovarian malignant melanoma associated with an ipsilateral carcinoid tumour and a contralateral
endometrioid adenocarcinoma. |
|
| Cerebral nocardia masquerading as metastatic CNS disease in an endometrial cancer patient |
90 |
N.B. Rettenmaier, H.D. Epstein, S. Oi, P.A. Robinson, B.H. Goldstein - Newport Beach, CA (USA)
A case of cerebral nocardia mimicking metastatic CNS disease in an endometrial cancer patient previously treated by surgery
and chemotherapy is presented. |
|
| Carcinosarcomas of the uterus and ovary: a clinicopathologic and immunohistochemical study of 11
cases |
93 |
A. Kondi-Pafiti, D. Grapsa, D. Hasakios, K. Gennatas, S. Fotiou - Athens, GREECE
Clinicopathologic and immunohistochemical features of 11 cases of carcinosarcomas located in the uterine corpus and the
ovary are presented. |
|
| Ovulation stimulation after treatment for a molar pregnancy - for or against? |
98 |
M. Gojnic, V. Dugalic, M. Brankovic, M. Pervulov, B. Vasiljevic, A. Fazlagic - Belgrade, SERBIA
A case of a 29-year-old patient who underwent in vitro fertilization due to secondary sterility, after a spontaneous but molar
pregnancy, is described. |
|
| Rectal cancer and pregnancy: report of two cases |
100 |
A. Kolusari, G. Ugurluer, C. Kotan, H.G. Sahin, M. Kamaci - Van, TURKEY
Two cases of pregnancy associated with rectal cancer are reported. |
|
| Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic
treatment for a presumed benign ovarian cyst |
103 |
D. Papoutsis, A. Rodolakis, D Haidopoulos, M. Sotiropoulou, A. Antsaklis - Athens, GREECE
A case of peritoneal implantations of a papillary serous ovarian cystadenocarcinoma 13 days after laparoscopic treatment for
an initially presumed benign ovarian cyst is presented. |
|
| Amelanotic malignant melanoma of the uterine cervix with ten years follow-up |
106 |
V.D. Mandato, B. Kobal, A. Di Stefano, J. Sinkovec, A. Levicnik, S. Rakar, L. Costagliola - Naples, ITALY
A case of a patient with amelanotic malignant melanoma of the cervix is described with particular attention to diagnostic procedures,
histopathological findings and therapy. |
|
| Primary adenocarcinoid tumor of the ovary arising in mature cystic teratoma. A case report |
110 |
T. Gungor, O. Altinkaya, M. Ozat, L. Sirvan, H. Yalcin, L. Mollamahmutoglu - Ankara, TURKEY
A case of a 47-year-old pregnant woman diagnosed with an ovarian adenocarcinoid tumor developing from a mature teratoma
is described. |
|
|